Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial results and operational challenges [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the July 14, 2025 deadline [2]. Group 2: Allegations Against Iovance - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to longer timelines and higher patient drop-offs [3]. - It is claimed that these issues resulted in increased costs and lower revenue for Iovance, as ATCs could not keep pace with the manufactured product, contradicting the company's positive statements about its business and prospects [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including securing over $438 million for investors in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly misleading investors about its business prospects, particularly regarding the launch dynamics of its cell therapy product, Amtagvi [1][2]. Company Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter, indicating a significant decline [3]. - The company revised its full fiscal year 2025 revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated revenue forecast reflects challenges with the growth trajectories and treatment timelines for new Authorized Treatment Centers (ATCs) [3]. Allegations and Investigation - The lawsuit alleges that Iovance failed to disclose critical issues, including longer timelines for new ATCs to begin treating patients, inefficiencies in patient identification and selection, and the resulting higher costs and lower revenues [2]. - The complaint claims that these undisclosed factors rendered the company's positive statements about its business and prospects materially misleading [2]. Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. due to alleged securities fraud that negatively impacted investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Iovance provided misleading positive statements while concealing material adverse facts about its growth potential, specifically its inability to generate demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Iovance Biotherapeutics has faced significant challenges following a downgrade by UBS analysts, who reduced their rating from Buy to Neutral and cut the price target from $17 to $2 due to concerns over the commercial rollout of its cell therapy, Amtagvi [1][3]. Company Performance - Iovance's first-quarter sales of Amtagvi fell short of Wall Street forecasts, prompting management to lower its full-year outlook [2]. - The company reported a quarterly loss of $0.36 per share on revenue of $49 million, missing consensus estimates significantly [5]. - Following the earnings announcement, Iovance's shares plummeted 44%, closing at $1.75, marking a dramatic decline for a company previously viewed as a leader in cell therapy [6]. Operational Challenges - UBS analysts highlighted a slower-than-expected ramp-up in sales, attributed to operational challenges at smaller authorized treatment centers, including limited hospital infrastructure, staffing shortages, and reimbursement uncertainties [2]. - A higher-than-anticipated patient dropout rate raised concerns about patient selection and the need for improved physician education [2]. Legal Issues - Iovance is currently facing a securities class action lawsuit, alleging that the company and its executives misrepresented growth prospects while withholding critical information about operational readiness [4][7]. - The lawsuit focuses on statements made between May 2024 and May 2025, during which the company's optimistic messaging was reportedly inconsistent with internal operational realities [4]. Investor Sentiment - The downgrade by UBS reflects broader investor unease regarding Amtagvi's near-term trajectory and Iovance's ability to meet market demand [3]. - The stock has lost over 80% of its value in the past year, indicating a significant decline in investor confidence [3].

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 20 ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Company Performance - Iovance Biotherapeutics reported a total product revenue of $49.3 million for Q1 2025, a significant decline from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [3]. - The updated revenue forecast reflects challenges with the launch dynamics of Amtagvi and the growth trajectories of Authorized Treatment Centers (ATCs) [3]. Allegations and Issues - The lawsuit claims that Iovance failed to disclose several critical issues, including: 1. New ATCs faced longer timelines to begin treating patients with Amtagvi [2]. 2. Ineffectiveness of the sales team and ATCs in patient identification and selection, leading to higher patient drop-offs [2]. 3. These dynamics resulted in higher costs and lower revenue due to ATCs not keeping pace with manufactured products [2]. 4. Positive statements made by the company regarding its business and prospects were materially misleading [2]. Legal Proceedings - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A securities class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly making false or misleading statements regarding its business operations and the commercialization of its product, Amtagvi, during the class period from May 9, 2024, to May 8, 2025 [1][3]. Company Overview - Iovance is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for metastatic melanoma and other solid tumor cancers [2]. - The company's primary product, Amtagvi, is a tumor-derived autologous T-cell immunotherapy approved by the FDA on February 16, 2024, and launched commercially on February 20, 2024 [2]. Allegations in the Class Action - The class action claims that during the class period, the defendants failed to disclose issues such as: - New Authorized Treatment Centers (ATCs) facing longer timelines to begin patient treatment with Amtagvi [3]. - Ineffectiveness of the sales team and new ATCs in identifying and selecting patients, leading to higher patient drop-offs [3]. - Resulting higher costs and lower revenue due to ATCs not keeping pace with manufactured product [3]. - Misleading positive statements about the company's business and prospects [3]. Financial Impact - On May 8, 2025, Iovance reported a significant decline in quarterly total product revenue to $49.3 million from $73.7 million in the previous quarter [4]. - The company revised its FY25 total product revenue guidance down from $450 million-$475 million to $250 million-$300 million, citing recent launch dynamics of Amtagvi [4]. - Following this announcement, Iovance's share price dropped by $1.42, or 44.8%, closing at $1.75 per share on May 9, 2025, with unusually high trading volume [4].

Core Viewpoint - Iovance Biotherapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and operational issues [1][2]. Financial Performance - For Q1 2025, Iovance reported a loss of $0.36 per share on revenue of $49 million, missing consensus estimates of a loss of $0.24 per share on revenue of $82 million [2]. - The company's operational bottleneck, caused by a 50% reduction in capacity at the Iovance Cell Therapy Center for a month in December 2024, limited the number of Amtagvi infusions available in Q1 [2]. Stock Market Reaction - Following the announcement of the financial results and operational issues, Iovance's stock price fell by $1.42 per share, or 44.79%, closing at $1.75 per share on May 9, 2025 [3].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs in driving demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient selection [4]. - The company reported disappointing financial results for Q1 2025, revising its full-year 2025 revenue guidance due to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - Following the announcement of poor financial results, Iovance's stock price fell over 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025 [6].